Companies › Artios Pharma
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ART0380 PARP inhibitor | – | Phase 1 | Advanced Cancer | Jan 2028 |
| ART6043 CHK1 inhibitor | – | Phase 1 | Advanced Solid Tumor | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04657068 | ART0380 | Phase 1 | Advanced Cancer | Oncology | Jan 2028 |
| NCT05898399 | ART6043 | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.